Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma
The identification of clinically viable strategies for overcoming resistance to platinum chemotherapy in lung adenocarcinoma has previously been hampered by inappropriately tailored in vitro assays of drug response. Therefore, using a pulse model that closely mimics the in vivo pharmacokinetics of p...
Uložené v:
| Vydané v: | eLife Ročník 9 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
England
eLife Sciences Publications Ltd
09.06.2020
eLife Sciences Publications, Ltd |
| Predmet: | |
| ISSN: | 2050-084X, 2050-084X |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | The identification of clinically viable strategies for overcoming resistance to platinum chemotherapy in lung adenocarcinoma has previously been hampered by inappropriately tailored in vitro assays of drug response. Therefore, using a pulse model that closely mimics the in vivo pharmacokinetics of platinum therapy, we profiled cisplatin-induced signalling, DNA-damage and apoptotic responses across a panel of human lung adenocarcinoma cell lines. By coupling this data to real-time, single-cell imaging of cell cycle and apoptosis we provide a fine-grained stratification of response, where a P70S6K-mediated signalling axis promotes resistance on a TP53 wildtype or null background, but not a mutant TP53 background. This finding highlights the value of in vitro models that match the physiological pharmacokinetics of drug exposure. Furthermore, it also demonstrates the importance of a mechanistic understanding of the interplay between somatic mutations and the signalling networks that govern drug response for the implementation of any consistently effective, patient-specific therapy.
Lung adenocarcinoma is the most common type of lung cancer, and it emerges because of a variety of harmful genetic changes, or mutations. Two lung cancer patients – or indeed, two different sets of cancerous cells within a patient – may therefore carry different damaging mutations.
A group of drugs called platinum-based chemotherapies are currently the most effective way to treat lung adenocarcinoma. Yet, only 30% of patients actually respond to the therapy. Many studies conducted in laboratory settings have tried to understand why most cases are resistant to treatment, with limited success.
Here, Hastings, Gonzalez-Rajal et al. propose that previous research has been inconclusive because studies done in the laboratory do not reflect how the treatment is actually administered. In patients, platinum-based drugs are cleared from the body within a few hours, but during experiments, the treatment is continually administered to cells growing in a dish.
Hastings, Gonzalez-Rajal et al. therefore developed a laboratory method that mimics the way cells are exposed to platinum-based chemotherapy in the body. These experiments showed that the lung adenocarcinoma cells which resisted treatment also carried high levels of a protein known as P70S6K. Pairing platinum-based chemotherapy with a drug that blocks the activity of P70S6K killed these resistant cells. This combination also treated human lung adenocarcinoma tumours growing under the skin of mice. However, it was ineffective on cancerous cells that carry a mutation in a protein called p53, which is often defective in cancers.
Overall, this work demonstrates the need to refine how drugs are tested in the laboratory to better reflect real-life conditions. It also underlines the importance of personalizing drug combinations to the genetic background of each tumour, a concept that will be vital to consider in future clinical trials. |
|---|---|
| AbstractList | The identification of clinically viable strategies for overcoming resistance to platinum chemotherapy in lung adenocarcinoma has previously been hampered by inappropriately tailored in vitro assays of drug response. Therefore, using a pulse model that closely mimics the in vivo pharmacokinetics of platinum therapy, we profiled cisplatin-induced signalling, DNA-damage and apoptotic responses across a panel of human lung adenocarcinoma cell lines. By coupling this data to real-time, single-cell imaging of cell cycle and apoptosis we provide a fine-grained stratification of response, where a P70S6K-mediated signalling axis promotes resistance on a TP53 wildtype or null background, but not a mutant TP53 background. This finding highlights the value of in vitro models that match the physiological pharmacokinetics of drug exposure. Furthermore, it also demonstrates the importance of a mechanistic understanding of the interplay between somatic mutations and the signalling networks that govern drug response for the implementation of any consistently effective, patient-specific therapy.The identification of clinically viable strategies for overcoming resistance to platinum chemotherapy in lung adenocarcinoma has previously been hampered by inappropriately tailored in vitro assays of drug response. Therefore, using a pulse model that closely mimics the in vivo pharmacokinetics of platinum therapy, we profiled cisplatin-induced signalling, DNA-damage and apoptotic responses across a panel of human lung adenocarcinoma cell lines. By coupling this data to real-time, single-cell imaging of cell cycle and apoptosis we provide a fine-grained stratification of response, where a P70S6K-mediated signalling axis promotes resistance on a TP53 wildtype or null background, but not a mutant TP53 background. This finding highlights the value of in vitro models that match the physiological pharmacokinetics of drug exposure. Furthermore, it also demonstrates the importance of a mechanistic understanding of the interplay between somatic mutations and the signalling networks that govern drug response for the implementation of any consistently effective, patient-specific therapy. The identification of clinically viable strategies for overcoming resistance to platinum chemotherapy in lung adenocarcinoma has previously been hampered by inappropriately tailored in vitro assays of drug response. Therefore, using a pulse model that closely mimics the in vivo pharmacokinetics of platinum therapy, we profiled cisplatin-induced signalling, DNA-damage and apoptotic responses across a panel of human lung adenocarcinoma cell lines. By coupling this data to real-time, single-cell imaging of cell cycle and apoptosis we provide a fine-grained stratification of response, where a P70S6K-mediated signalling axis promotes resistance on a TP53 wildtype or null background, but not a mutant TP53 background. This finding highlights the value of in vitro models that match the physiological pharmacokinetics of drug exposure. Furthermore, it also demonstrates the importance of a mechanistic understanding of the interplay between somatic mutations and the signalling networks that govern drug response for the implementation of any consistently effective, patient-specific therapy. Lung adenocarcinoma is the most common type of lung cancer, and it emerges because of a variety of harmful genetic changes, or mutations. Two lung cancer patients – or indeed, two different sets of cancerous cells within a patient – may therefore carry different damaging mutations. A group of drugs called platinum-based chemotherapies are currently the most effective way to treat lung adenocarcinoma. Yet, only 30% of patients actually respond to the therapy. Many studies conducted in laboratory settings have tried to understand why most cases are resistant to treatment, with limited success. Here, Hastings, Gonzalez-Rajal et al. propose that previous research has been inconclusive because studies done in the laboratory do not reflect how the treatment is actually administered. In patients, platinum-based drugs are cleared from the body within a few hours, but during experiments, the treatment is continually administered to cells growing in a dish. Hastings, Gonzalez-Rajal et al. therefore developed a laboratory method that mimics the way cells are exposed to platinum-based chemotherapy in the body. These experiments showed that the lung adenocarcinoma cells which resisted treatment also carried high levels of a protein known as P70S6K. Pairing platinum-based chemotherapy with a drug that blocks the activity of P70S6K killed these resistant cells. This combination also treated human lung adenocarcinoma tumours growing under the skin of mice. However, it was ineffective on cancerous cells that carry a mutation in a protein called p53, which is often defective in cancers. Overall, this work demonstrates the need to refine how drugs are tested in the laboratory to better reflect real-life conditions. It also underlines the importance of personalizing drug combinations to the genetic background of each tumour, a concept that will be vital to consider in future clinical trials. The identification of clinically viable strategies for overcoming resistance to platinum chemotherapy in lung adenocarcinoma has previously been hampered by inappropriately tailored in vitro assays of drug response. Therefore, using a pulse model that closely mimics the in vivo pharmacokinetics of platinum therapy, we profiled cisplatin-induced signalling, DNA-damage and apoptotic responses across a panel of human lung adenocarcinoma cell lines. By coupling this data to real-time, single-cell imaging of cell cycle and apoptosis we provide a fine-grained stratification of response, where a P70S6K-mediated signalling axis promotes resistance on a TP53 wildtype or null background, but not a mutant TP53 background. This finding highlights the value of in vitro models that match the physiological pharmacokinetics of drug exposure. Furthermore, it also demonstrates the importance of a mechanistic understanding of the interplay between somatic mutations and the signalling networks that govern drug response for the implementation of any consistently effective, patient-specific therapy. The identification of clinically viable strategies for overcoming resistance to platinum chemotherapy in lung adenocarcinoma has previously been hampered by inappropriately tailored in vitro assays of drug response. Therefore, using a pulse model that closely mimics the in vivo pharmacokinetics of platinum therapy, we profiled cisplatin-induced signalling, DNA-damage and apoptotic responses across a panel of human lung adenocarcinoma cell lines. By coupling this data to real-time, single-cell imaging of cell cycle and apoptosis we provide a fine-grained stratification of response, where a P70S6K-mediated signalling axis promotes resistance on a wildtype or null background, but not a mutant background. This finding highlights the value of in vitro models that match the physiological pharmacokinetics of drug exposure. Furthermore, it also demonstrates the importance of a mechanistic understanding of the interplay between somatic mutations and the signalling networks that govern drug response for the implementation of any consistently effective, patient-specific therapy. The identification of clinically viable strategies for overcoming resistance to platinum chemotherapy in lung adenocarcinoma has previously been hampered by inappropriately tailored in vitro assays of drug response. Therefore, using a pulse model that closely mimics the in vivo pharmacokinetics of platinum therapy, we profiled cisplatin-induced signalling, DNA-damage and apoptotic responses across a panel of human lung adenocarcinoma cell lines. By coupling this data to real-time, single-cell imaging of cell cycle and apoptosis we provide a fine-grained stratification of response, where a P70S6K-mediated signalling axis promotes resistance on a TP53 wildtype or null background, but not a mutant TP53 background. This finding highlights the value of in vitro models that match the physiological pharmacokinetics of drug exposure. Furthermore, it also demonstrates the importance of a mechanistic understanding of the interplay between somatic mutations and the signalling networks that govern drug response for the implementation of any consistently effective, patient-specific therapy. Lung adenocarcinoma is the most common type of lung cancer, and it emerges because of a variety of harmful genetic changes, or mutations. Two lung cancer patients – or indeed, two different sets of cancerous cells within a patient – may therefore carry different damaging mutations. A group of drugs called platinum-based chemotherapies are currently the most effective way to treat lung adenocarcinoma. Yet, only 30% of patients actually respond to the therapy. Many studies conducted in laboratory settings have tried to understand why most cases are resistant to treatment, with limited success. Here, Hastings, Gonzalez-Rajal et al. propose that previous research has been inconclusive because studies done in the laboratory do not reflect how the treatment is actually administered. In patients, platinum-based drugs are cleared from the body within a few hours, but during experiments, the treatment is continually administered to cells growing in a dish. Hastings, Gonzalez-Rajal et al. therefore developed a laboratory method that mimics the way cells are exposed to platinum-based chemotherapy in the body. These experiments showed that the lung adenocarcinoma cells which resisted treatment also carried high levels of a protein known as P70S6K. Pairing platinum-based chemotherapy with a drug that blocks the activity of P70S6K killed these resistant cells. This combination also treated human lung adenocarcinoma tumours growing under the skin of mice. However, it was ineffective on cancerous cells that carry a mutation in a protein called p53, which is often defective in cancers. Overall, this work demonstrates the need to refine how drugs are tested in the laboratory to better reflect real-life conditions. It also underlines the importance of personalizing drug combinations to the genetic background of each tumour, a concept that will be vital to consider in future clinical trials. |
| Author | Daneshvar, Dariush Burgess, Andrew Hastings, Jordan F Nagrial, Adnan Watkins, D Neil Gonzalez Rajal, Alvaro Murphy, Alexander D O'Donnell, Yolande EI Chin, Venessa Latham, Sharissa L Han, Jeremy ZR Phimmachanh, Monica Croucher, David R McCloy, Rachael A |
| Author_xml | – sequence: 1 givenname: Jordan F surname: Hastings fullname: Hastings, Jordan F organization: The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, Australia – sequence: 2 givenname: Alvaro surname: Gonzalez Rajal fullname: Gonzalez Rajal, Alvaro organization: The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, Australia – sequence: 3 givenname: Sharissa L surname: Latham fullname: Latham, Sharissa L organization: The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, Australia, St Vincent's Hospital Clinical School, University of New South Wales, Sydney, Australia – sequence: 4 givenname: Jeremy ZR surname: Han fullname: Han, Jeremy ZR organization: The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, Australia – sequence: 5 givenname: Rachael A surname: McCloy fullname: McCloy, Rachael A organization: The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, Australia – sequence: 6 givenname: Yolande EI surname: O'Donnell fullname: O'Donnell, Yolande EI organization: The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, Australia – sequence: 7 givenname: Monica surname: Phimmachanh fullname: Phimmachanh, Monica organization: The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, Australia – sequence: 8 givenname: Alexander D surname: Murphy fullname: Murphy, Alexander D organization: Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals, Sydney, Australia – sequence: 9 givenname: Adnan surname: Nagrial fullname: Nagrial, Adnan organization: Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals, Sydney, Australia – sequence: 10 givenname: Dariush surname: Daneshvar fullname: Daneshvar, Dariush organization: Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals, Sydney, Australia – sequence: 11 givenname: Venessa surname: Chin fullname: Chin, Venessa organization: The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, Australia, St Vincent's Hospital Clinical School, University of New South Wales, Sydney, Australia, St Vincent’s Hospital Sydney, Darlinghurst, Australia – sequence: 12 givenname: D Neil surname: Watkins fullname: Watkins, D Neil organization: Hudson Institute of Medical Research, Victoria, Australia, Department of Molecular and Translational Medicine, School of Medicine, Nursing and Health Sciences, Monash University, Victoria, Australia, Research Institute in Oncology and Hematology, Cancer Care Manitoba, Winnipeg, Canada, Department of Internal Medicine, Rady Faculty of Health Science, University of Manitoba, Winnipeg, Canada – sequence: 13 givenname: Andrew orcidid: 0000-0003-4536-9226 surname: Burgess fullname: Burgess, Andrew organization: ANZAC Research Institute, Concord, Australia, The University of Sydney Concord Clinical School, Faculty of Medicine and Health, Sydney, Australia – sequence: 14 givenname: David R orcidid: 0000-0003-4965-8674 surname: Croucher fullname: Croucher, David R organization: The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, Australia, St Vincent's Hospital Clinical School, University of New South Wales, Sydney, Australia, School of Medicine, University College Dublin, Belfield, Dublin, Ireland |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32513387$$D View this record in MEDLINE/PubMed |
| BookMark | eNptks9rVDEQx4NUbK09eZcHXgTZmt_Juwil-KOw4EXBW8jLS9Ys2WRN3hP2v3f6tpa2ODkkZD7zzUxmXqKTXLJH6DXBl0oI_sGvY_CXgjGpnqEzigVeYc1_njw4n6KL1rYYTHGtSf8CnTIqCGNanaHtVbbp0GLrSuj2c2p-7Fxs-2SnmLsWN-BOMW-68ZDtLrrWxdHnKYboW-dD8G4qdQmuHlQmm53vIDLNEGMBLc5WF3PZ2VfoebDwwMXdfo5-fP70_frrav3ty8311XrluBLTSvQ9kdoNobeit9ZrFjDjenRCO85H5vtAqaRSETEECZAceoo1USGwMGDLztHNUXcsdmv2Ne5sPZhio1kuSt0YW6fokjfSjY5a7HopFOeeDYwIySXVo9ZMCQlaH49a-3nY-dFB6dWmR6KPPTn-MpvyxyiqYWEQeHcnUMvv2bfJ7GJzPiWbfZmboZyAYU4VoG-foNsyV_j_hdK9YpgToN48zOg-lX8tBeD9EXC1tFZ9uEcINrczY5aZMcvMAE2e0C5O0PtyW05M_435CxsLxfs |
| CitedBy_id | crossref_primary_10_1177_15330338241274337 crossref_primary_10_3390_cancers13092073 crossref_primary_10_1016_j_ceb_2021_04_007 crossref_primary_10_7554_eLife_65234 crossref_primary_10_1186_s40170_021_00278_1 crossref_primary_10_1080_15384101_2022_2031770 crossref_primary_10_1038_s41467_025_62934_0 crossref_primary_10_1073_pnas_2415869122 |
| Cites_doi | 10.1371/journal.pone.0028406 10.1038/s41420-018-0060-7 10.1126/scisignal.aab0990 10.1158/2159-8290.CD-12-0095 10.1016/j.jtho.2017.12.001 10.1016/j.cell.2007.12.033 10.1038/363170a0 10.18632/oncotarget.23711 10.1158/1078-0432.CCR-04-0941 10.1074/jbc.M109.040667 10.1186/s13058-019-1127-y 10.1098/rstb.2013.0109 10.1046/j.1359-4117.2002.01019.x 10.1038/nbt.2786 10.1517/14728222.2012.684680 10.1128/MCB.17.9.5648 10.3390/ijms19030767 10.1038/cdd.2017.172 10.4161/cc.21194 10.1038/nrc3775 10.1158/1078-0432.CCR-18-1538 10.1126/scisignal.2004088 10.1021/cr980421n 10.1002/jcp.24521 10.1126/scitranslmed.aat3504 10.1124/pr.111.005637 10.1016/j.cell.2018.03.022 10.3892/ijo.2014.2505 10.1080/15384101.2014.1000134 10.1136/thoraxjnl-2014-205914 10.1021/js960037a 10.1002/emmm.201302732 10.1371/journal.pone.0182891 10.1371/journal.pone.0082241 10.1038/sj.onc.1206608 10.1016/j.cllc.2019.05.009 10.1038/sj.ki.5002786 10.1016/j.critrevonc.2007.02.001 10.1016/j.canlet.2006.11.008 |
| ContentType | Journal Article |
| Copyright | 2020, Hastings et al. 2020, Hastings et al. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2020, Hastings et al 2020 Hastings et al |
| Copyright_xml | – notice: 2020, Hastings et al. – notice: 2020, Hastings et al. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2020, Hastings et al 2020 Hastings et al |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
| DOI | 10.7554/eLife.53367 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Science Database ProQuest Biological Science ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2050-084X |
| ExternalDocumentID | oai_doaj_org_article_6cdc2a0c965744e3b31564628d883756 PMC7282820 32513387 10_7554_eLife_53367 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Cancer Institute NSW grantid: 15/REG/1-17 – fundername: Cancer Institute NSW grantid: 2013/FRL102 – fundername: ; grantid: 15/REG/1-17 – fundername: ; grantid: 2013/FRL102 |
| GroupedDBID | 53G 5VS 7X7 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAKDD AAYXX ABUWG ACGFO ACGOD ACPRK ADBBV ADRAZ AENEX AFFHD AFKRA AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI CCPQU CITATION DIK DWQXO EMOBN FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IEA IHR INH INR ISR ITC KQ8 LK8 M1P M2P M48 M7P M~E NQS OK1 PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO RHI RNS RPM UKHRP 3V. ALIPV CGR CUY CVF ECM EIF FRP NPM RHF 7XB 8FK K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c475t-599168cbf9a59aae83f0348dc58c44d3e9f22626715bf69a56b920817ff3fb0a3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 9 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000541447200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2050-084X |
| IngestDate | Fri Oct 03 12:42:01 EDT 2025 Tue Nov 04 01:58:45 EST 2025 Fri Sep 05 06:58:08 EDT 2025 Tue Oct 07 07:01:15 EDT 2025 Thu Jan 02 22:58:14 EST 2025 Sat Nov 29 06:23:43 EST 2025 Tue Nov 18 20:51:13 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | chemoresistance signalling dynamics lung adenocarcinoma cancer biology human platinum chemotherapy P70S6K p53 |
| Language | English |
| License | http://creativecommons.org/licenses/by/4.0 2020, Hastings et al. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c475t-599168cbf9a59aae83f0348dc58c44d3e9f22626715bf69a56b920817ff3fb0a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 These authors contributed equally to this work. |
| ORCID | 0000-0003-4536-9226 0000-0003-4965-8674 |
| OpenAccessLink | https://doaj.org/article/6cdc2a0c965744e3b31564628d883756 |
| PMID | 32513387 |
| PQID | 2418973041 |
| PQPubID | 2045579 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_6cdc2a0c965744e3b31564628d883756 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7282820 proquest_miscellaneous_2411110427 proquest_journals_2418973041 pubmed_primary_32513387 crossref_primary_10_7554_eLife_53367 crossref_citationtrail_10_7554_eLife_53367 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-06-09 |
| PublicationDateYYYYMMDD | 2020-06-09 |
| PublicationDate_xml | – month: 06 year: 2020 text: 2020-06-09 day: 09 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Cambridge |
| PublicationTitle | eLife |
| PublicationTitleAlternate | Elife |
| PublicationYear | 2020 |
| Publisher | eLife Sciences Publications Ltd eLife Sciences Publications, Ltd |
| Publisher_xml | – name: eLife Sciences Publications Ltd – name: eLife Sciences Publications, Ltd |
| References | Hoffmann (bib17) 2014; 369 Győrffy (bib13) 2013; 8 Kennedy (bib24) 2019; 21 Pereira (bib33) 2013; 5 Galan-Moya (bib9) 2011; 6 Sahin (bib35) 2004; 10 Sakaue-Sawano (bib36) 2008; 132 Kim (bib25) 2019; 20 Shen (bib38) 2012; 64 Guégan (bib12) 2014; 229 Sarin (bib37) 2018; 19 Holz (bib18) 2012; 11 Moser (bib30) 1997; 17 Pilkington (bib34) 2015; 70 Ip (bib21) 2012; 16 Gire (bib11) 2015; 14 Hay (bib14) 2014; 32 Huang (bib20) 2018; 9 Nozawa (bib31) 2007; 251 Fey (bib8) 2015; 8 Jamieson (bib22) 1999; 99 Lane (bib26) 1993; 363 Doroshow (bib6) 2019; 25 Johansen (bib23) 2002; 2 Chen (bib4) 2014; 14 Sunami (bib40) 2010; 285 Chen (bib5) 2017; 12 Engeland (bib7) 2018; 25 Hsu (bib19) 2018; 4 Bonanno (bib2) 2014; 34 Hoadley (bib16) 2018; 173 Hernández Losa (bib15) 2003; 22 Pabla (bib32) 2008; 73 Gao (bib10) 2013; 6 Lindeman (bib27) 2018; 13 Cerami (bib3) 2012; 2 Marini (bib28) 2018; 10 Moon (bib29) 2014; 45 Stewart (bib39) 2007; 63 Andersson (bib1) 1996; 85 |
| References_xml | – volume: 6 year: 2011 ident: bib9 article-title: Balance between MKK6 and MKK3 mediates p38 MAPK associated resistance to cisplatin in NSCLC publication-title: PLOS ONE doi: 10.1371/journal.pone.0028406 – volume: 4 year: 2018 ident: bib19 article-title: NVP-BEZ235, a dual PI3K-mTOR inhibitor, suppresses the growth of FaDu hypopharyngeal squamous cell carcinoma and has a synergistic effect with cisplatin publication-title: Cell Death Discovery doi: 10.1038/s41420-018-0060-7 – volume: 8 year: 2015 ident: bib8 article-title: Signaling pathway models as biomarkers: patient-specific simulations of JNK activity predict the survival of neuroblastoma patients publication-title: Science Signaling doi: 10.1126/scisignal.aab0990 – volume: 2 start-page: 401 year: 2012 ident: bib3 article-title: The cBio Cancer genomics portal: an open platform for exploring multidimensional Cancer genomics data publication-title: Cancer Discovery doi: 10.1158/2159-8290.CD-12-0095 – volume: 13 start-page: 323 year: 2018 ident: bib27 article-title: Updated molecular testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology publication-title: Journal of Oncol doi: 10.1016/j.jtho.2017.12.001 – volume: 132 start-page: 487 year: 2008 ident: bib36 article-title: Visualizing spatiotemporal dynamics of multicellular cell-cycle progression publication-title: Cell doi: 10.1016/j.cell.2007.12.033 – volume: 363 start-page: 170 year: 1993 ident: bib26 article-title: p70s6k function is essential for G1 progression publication-title: Nature doi: 10.1038/363170a0 – volume: 9 start-page: 10483 year: 2018 ident: bib20 article-title: NVP-BEZ235 synergizes cisplatin sensitivity in osteosarcoma publication-title: Oncotarget doi: 10.18632/oncotarget.23711 – volume: 10 start-page: 8421 year: 2004 ident: bib35 article-title: mTOR and P70 S6 kinase expression in primary liver neoplasms publication-title: Clinical Cancer Research doi: 10.1158/1078-0432.CCR-04-0941 – volume: 285 start-page: 4587 year: 2010 ident: bib40 article-title: Structural basis of human p70 ribosomal S6 kinase-1 regulation by activation loop phosphorylation publication-title: Journal of Biological Chemistry doi: 10.1074/jbc.M109.040667 – volume: 21 year: 2019 ident: bib24 article-title: Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast Cancer publication-title: Breast Cancer Research doi: 10.1186/s13058-019-1127-y – volume: 369 year: 2014 ident: bib17 article-title: Ion channels and transporters in the development of drug resistance in Cancer cells publication-title: Philosophical Transactions of the Royal Society B: Biological Sciences doi: 10.1098/rstb.2013.0109 – volume: 2 start-page: 163 year: 2002 ident: bib23 article-title: Use of microdialysis to study platinum anticancer agent pharmacokinetics in preclinical models publication-title: Journal of Experimental Therapeutics and Oncology doi: 10.1046/j.1359-4117.2002.01019.x – volume: 32 start-page: 40 year: 2014 ident: bib14 article-title: Clinical development success rates for investigational drugs publication-title: Nature Biotechnology doi: 10.1038/nbt.2786 – volume: 16 start-page: 619 year: 2012 ident: bib21 article-title: Exploiting p70 S6 kinase as a target for ovarian Cancer publication-title: Expert Opinion on Therapeutic Targets doi: 10.1517/14728222.2012.684680 – volume: 17 start-page: 5648 year: 1997 ident: bib30 article-title: Dual requirement for a newly identified phosphorylation site in p70s6k publication-title: Molecular and Cellular Biology doi: 10.1128/MCB.17.9.5648 – volume: 19 year: 2018 ident: bib37 article-title: Key players of cisplatin resistance: towards a systems pharmacology approach publication-title: International Journal of Molecular Sciences doi: 10.3390/ijms19030767 – volume: 25 start-page: 114 year: 2018 ident: bib7 article-title: Cell cycle arrest through indirect transcriptional repression by p53: i have a DREAM publication-title: Cell Death & Differentiation doi: 10.1038/cdd.2017.172 – volume: 11 start-page: 3159 year: 2012 ident: bib18 article-title: The role of S6K1 in ER-positive breast Cancer publication-title: Cell Cycle doi: 10.4161/cc.21194 – volume: 14 start-page: 535 year: 2014 ident: bib4 article-title: Non-small-cell lung cancers: a heterogeneous set of diseases publication-title: Nature Reviews Cancer doi: 10.1038/nrc3775 – volume: 25 start-page: 4592 year: 2019 ident: bib6 article-title: Immunotherapy in Non-Small cell lung Cancer: facts and hopes publication-title: Clinical Cancer Research doi: 10.1158/1078-0432.CCR-18-1538 – volume: 6 year: 2013 ident: bib10 article-title: Integrative analysis of complex Cancer genomics and clinical profiles using the cBioPortal publication-title: Science Signaling doi: 10.1126/scisignal.2004088 – volume: 99 start-page: 2467 year: 1999 ident: bib22 article-title: Structure, recognition, and processing of Cisplatin-DNA adducts publication-title: Chemical Reviews doi: 10.1021/cr980421n – volume: 229 start-page: 903 year: 2014 ident: bib12 article-title: MEK1/2 overactivation can promote growth arrest by mediating ERK1/2-dependent phosphorylation of p70S6K publication-title: Journal of Cellular Physiology doi: 10.1002/jcp.24521 – volume: 10 year: 2018 ident: bib28 article-title: Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy publication-title: Science Translational Medicine doi: 10.1126/scitranslmed.aat3504 – volume: 64 start-page: 706 year: 2012 ident: bib38 article-title: Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes publication-title: Pharmacological Reviews doi: 10.1124/pr.111.005637 – volume: 173 start-page: 291 year: 2018 ident: bib16 article-title: Cell-of-Origin patterns dominate the molecular classification of 10,000 tumors from 33 types of Cancer publication-title: Cell doi: 10.1016/j.cell.2018.03.022 – volume: 45 start-page: 1027 year: 2014 ident: bib29 article-title: NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder Cancer cells publication-title: International Journal of Oncology doi: 10.3892/ijo.2014.2505 – volume: 14 start-page: 297 year: 2015 ident: bib11 article-title: Senescence from G2 arrest, revisited publication-title: Cell Cycle doi: 10.1080/15384101.2014.1000134 – volume: 34 start-page: 493 year: 2014 ident: bib2 article-title: Platinum drugs and DNA repair mechanisms in lung Cancer publication-title: Anticancer Research – volume: 70 start-page: 359 year: 2015 ident: bib34 article-title: A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung Cancer publication-title: Thorax doi: 10.1136/thoraxjnl-2014-205914 – volume: 85 start-page: 824 year: 1996 ident: bib1 article-title: Pharmacokinetics of cisplatin and its monohydrated complex in humans publication-title: Journal of Pharmaceutical Sciences doi: 10.1021/js960037a – volume: 5 start-page: 1759 year: 2013 ident: bib33 article-title: Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK publication-title: EMBO Molecular Medicine doi: 10.1002/emmm.201302732 – volume: 12 year: 2017 ident: bib5 article-title: Hyperphosphorylation of RPS6KB1, rather than overexpression, predicts worse prognosis in non-small cell lung Cancer patients publication-title: PLOS ONE doi: 10.1371/journal.pone.0182891 – volume: 8 year: 2013 ident: bib13 article-title: Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung Cancer publication-title: PLOS ONE doi: 10.1371/journal.pone.0082241 – volume: 22 start-page: 3998 year: 2003 ident: bib15 article-title: Role of the p38 MAPK pathway in cisplatin-based therapy publication-title: Oncogene doi: 10.1038/sj.onc.1206608 – volume: 20 start-page: 331 year: 2019 ident: bib25 article-title: First-line pembrolizumab versus pembrolizumab plus chemotherapy versus chemotherapy alone in Non-small-cell lung Cancer: a systematic review and network Meta-analysis publication-title: Clinical Lung Cancer doi: 10.1016/j.cllc.2019.05.009 – volume: 73 start-page: 994 year: 2008 ident: bib32 article-title: Cisplatin nephrotoxicity: mechanisms and renoprotective strategies publication-title: Kidney International doi: 10.1038/sj.ki.5002786 – volume: 63 start-page: 12 year: 2007 ident: bib39 article-title: Mechanisms of resistance to cisplatin and carboplatin publication-title: Critical Reviews in Oncology/Hematology doi: 10.1016/j.critrevonc.2007.02.001 – volume: 251 start-page: 105 year: 2007 ident: bib31 article-title: Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal Cancer publication-title: Cancer Letters doi: 10.1016/j.canlet.2006.11.008 |
| SSID | ssj0000748819 |
| Score | 2.3057694 |
| Snippet | The identification of clinically viable strategies for overcoming resistance to platinum chemotherapy in lung adenocarcinoma has previously been hampered by... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| SubjectTerms | Adenocarcinoma Adenocarcinoma of Lung - metabolism Adenocarcinoma of Lung - pathology Antibodies Antineoplastic Agents - pharmacology Apoptosis Apoptosis - drug effects Cancer Biology Cancer therapies Cell cycle Cell Cycle - drug effects Cell Line, Tumor chemoresistance Chemotherapy Cisplatin Cisplatin - pharmacology Deoxyribonucleic acid Dimensional analysis DNA DNA damage Drug dosages Drug Resistance, Neoplasm Humans Investigations lung adenocarcinoma Lung cancer Lung Neoplasms - metabolism Lung Neoplasms - pathology Mutation p53 p53 Protein P70S6K Pharmacokinetics Physiology Platinum platinum chemotherapy Proteins Response rates Signal Transduction - drug effects signalling dynamics Tumor cell lines |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BAYkL70KgICP1hBS6iePYPlUFUXGoKg4g7S1y_ICgkmyTXST-PTNONmVRxYUc40liacaeb8aT-QAOhfAh91mdonPDACXUuA-6gDEP96XlTggRImvJmTw_V8ul_jQl3IaprHK7J8aN2nWWcuRH6GmURnMssuPVZUqsUXS6OlFo3IRbRJtNdi6Xcs6xoHtU6PHG3_IkOs4jf9YE_xYhTuSVv3JEsV__dSDz71rJP5zP6f3_nfYDuDfBTnYy2slDuOHbR3BnJKL89Ri-b3uTsC6w1QbdpWO2GVZUKNcyqvEwsXc3cyOB_cAaN5YZ-YGNJSFdHx_G6J0QKZoSwycvcCthBkXRY_a2absf5gl8Of3w-f3HdGJhSG0hxToVhCCVrYM2QhvjFQ8LXihnhbJF4bjXASFcXspM1KFEobLWOQINGQIP9cLwfdhru9Y_A4ZYJlhEKLXFN2SW68JnHjGc9RnHj8kE3mxVUtmpRTkxZVxUGKqQ_qqovyrqL4HDWXg1dua4Xuwd6XYWoXba8UbXf62m1VmV1tncLKwuhSwKz2tOPXTKXDmFAbwoEzjYarea1vhQXak2gdfzMK5OOnIxre82UQYv4jNJ4OloSPNMeE7cOgpH5I6J7Ux1d6RtvsUO4JIC5Xzx_N_TegF3c8oOUM5IH8Deut_4l3Db_lw3Q_8qLpXftX8g0w priority: 102 providerName: ProQuest |
| Title | Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32513387 https://www.proquest.com/docview/2418973041 https://www.proquest.com/docview/2411110427 https://pubmed.ncbi.nlm.nih.gov/PMC7282820 https://doaj.org/article/6cdc2a0c965744e3b31564628d883756 |
| Volume | 9 |
| WOSCitedRecordID | wos000541447200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2050-084X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000748819 issn: 2050-084X databaseCode: DOA dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2050-084X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000748819 issn: 2050-084X databaseCode: M~E dateStart: 20120101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2050-084X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000748819 issn: 2050-084X databaseCode: 7X7 dateStart: 20120101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Biological Science customDbUrl: eissn: 2050-084X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000748819 issn: 2050-084X databaseCode: M7P dateStart: 20120101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2050-084X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000748819 issn: 2050-084X databaseCode: BENPR dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2050-084X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000748819 issn: 2050-084X databaseCode: PIMPY dateStart: 20120101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 2050-084X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000748819 issn: 2050-084X databaseCode: M2P dateStart: 20120101 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fb9MwED7BBhIviN8ERmWkPSGVJXYc248MbQJpqyIEUnmKHMcWQSOpmnbS_nvOdlpaNIkX-uCH-tK6l7Pvu_b6fQDHnFtHbVZPMblhgeJqPAcbhzUPs4VhDefcBdWSCzGbyflclTtSX74nLNIDR8edFKYxVKdGFVzkuWU18_QmBZWNxNqKB7LtVKidYiqcwQIDM1PxD3kCU-aJvWidfY_gJijK_0lBgan_Nnj5d5fkTto5fwQPR7xIPsR1PoY7tnsC96OC5M1T-LkhFSG9I4s15rmGmHZY-A63jvjmDB1It0kTlecH0jaxP8gOJPZy9MtwMZbdHkpiDBC88grPAKLRFFPd0rRd_0s_g2_nZ18_fpqO8glTkwu-mnIP_aSpndJcaW0lcynLZWO4NHneMKscYi9aiIzXrkCjolYUEYJwjrk61ew5HHR9Z18CQRDiDEKL2uArZIap3GYWwZexGcM3Ewm823i0MiO3uJe4uKqwxvDur4L7q-D-BI63xotIqXG72am_NVsTz4MdnsDoqMboqP4VHQkcbW5sNW7OoULQIhWebHmWwNvtNG4r_1uJ7my_Djb48EIkCbyIcbBdCaNeFEfijNiLkL2l7s907Y9A3S18hUvTV__js72GB9QX__4rIXUEB6vl2r6Be-Z61Q7LCdwVcxFGOYHD07NZ-WUS9giOl7T0o8DxsPx8WX7_DfiLGJE |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VAioX3o9AASOVC1JoYseJc0CIV9Wqy6qHIvWWJn7QoDZZkl3Q_il-I2PnURZV3Hpgj_Ek6918nvk8mcwHsMW5NlSHhY_BDTcopkA_qAzueZiOJVOcc-NUSybJdCqOjtKDNfg1vAtjyyoHn-gctaqlzZFvY6QRKcIxCt_OvvtWNco-XR0kNDpY7OvlT9yytW_2PuL9fUnpzqfDD7t-ryrgyyjhc59bRiRkYdKcp3muBTMBi4SSXMgoUkynBikJjZOQFyZGo7hIKQbOxBhmiiBneN0rcBVpBA1cqeDBmNPBcCwwwnavASYYqLf1pDT6NVIqp2N_HvicPsBFpPbv2sw_gt3Orf_tb7oNN3taTd516-AOrOnqLlzvhDaX9-Db0HuF1IbMFkgHFJFlO7OFgBWxNSy5601O1LLKz0rZklJ1ZVS6JV3JS924kxvdWsaNS4XgmafoKkmOpsgIGllW9Vl-H75cyg99AOtVXelHQJCrGYkMrJB4hVCyNNKhRo4qdcjwyxIPXg0QyGTfgt0qgZxmuBWzeMkcXjKHFw-2RuNZ13nkYrP3FkujiW0X7g7Uzdes9z5ZLJWkeSDTmCdRpFnBbI-gmAolBEt47MHmgKas92Ftdg4lD16Mw-h97COlvNL1wtngx-q1ePCwA-44E0atdpDAkWQF0itTXR2pyhPX4TyxiQAaPP73tJ7Dxu7h50k22ZvuP4Eb1GZCbH4s3YT1ebPQT-Ga_DEv2-aZW6YEji8b8L8BSHl9Tw |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lj9MwEB4tXUBceD8CCxhpuSCFNnEcOweEgKWi2lL1ANJyCokfELSblKQF9a_x6xg7SZeiFbc90GM8Sd3m88znyWQ-gH3GtAl1kPsY3HCDYnL0g8rgnofqWFLFGDNOtWTKZzNxdJTMd-BX_y6MLavsfaJz1KqSNkc-xEgjEoRjFAxNVxYxPxi_XHz3rYKUfdLay2m0EDnU65-4fWteTA7wXj8Nw_HbD2_e-Z3CgC8jzpY-s-xIyNwkGUuyTAtqRjQSSjIho0hRnRikJ2HMA5abGI3iPAkxiHJjqMlHGcXrXoBdbvV7B7A7n7yff9pkeDA4C4y37UuBHMP2UE8Lo58jwXKq9qdh0KkFnEVx_67U_CP0ja_9z3_adbjaEW7yql0hN2BHlzfhUivBub4F3_quLKQyZLFCoqCILJqFLREsia1uyVzXcqLWZXZSyIYUqi2w0g1pi2Gq2p1c68ZycVxEBM88RidKMjRFrlDLoqxOstvw8Vx-6B0YlFWp7wFBFmckcrNc4hUCSZNIBxrZq9QBxS_jHjzr4ZDKrjm71Qg5TnGTZrGTOuykDjse7G-MF21PkrPNXltcbUxsI3F3oKq_pJ1fSmOpZJiNZBIzHkWa5tR2D4pDoYSgnMUe7PXISjvv1qSnsPLgyWYY_ZJ92JSVulo5G_xYJRcP7rYg3syEhlZVSOAI34L31lS3R8riq-t9zm2KIBzd__e0HsNlxHk6ncwOH8CV0KZIbOIs2YPBsl7ph3BR_lgWTf2oW7MEPp834n8DSiiHlg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Analysis+of+pulsed+cisplatin+signalling+dynamics+identifies+effectors+of+resistance+in+lung+adenocarcinoma&rft.jtitle=eLife&rft.au=Hastings%2C+Jordan+F&rft.au=Gonzalez+Rajal%2C+Alvaro&rft.au=Latham%2C+Sharissa+L&rft.au=Han%2C+Jeremy+ZR&rft.date=2020-06-09&rft.issn=2050-084X&rft.eissn=2050-084X&rft.volume=9&rft_id=info:doi/10.7554%2FeLife.53367&rft.externalDBID=n%2Fa&rft.externalDocID=10_7554_eLife_53367 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2050-084X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2050-084X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2050-084X&client=summon |